In accordance with this, tumour infiltrated CD8+CD103+ TRM cells (resident memory CD8+ T cells) has been associated with prolonged survival and better prognosis in ovarian [501], endometrial [502], breast [503] and lung cancer patients [504]. This evidence concerns the gene CD8A and neoplasm.